La vendita allo scoperto per Castor Maritime dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Castor Maritime. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Castor Maritime (NASDAQ:CTRM) Azioni, Report sulle vendite allo scoperto

Castor Maritime

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under two reportable segments namely Dry bulk; Aframax/LR2 tanker; Handysize tanker and Container ship. It generates maximum revenue from the Dry bulk segment.

Castor Maritime Inc

The collaboration supports the licensing of part of Curiosity Stream&#39;s content portfolio in China, Hong Kong, and Macau, bringing 56 unique titles, amounting to 148 hours of premium factual content, to audiences across these territories through various platforms. The deal encompasses a diverse range of programming, from short-form documentary series to premium long-form content.

News

CURI

Curiosity Inks Strategic Distribution Partnership With Off The Fence; Deal Broadens Company's Footprint Across China, Hong Kong, And Macau

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Needham analyst Kyle Peterson reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $350 price target.

Needham Reiterates Buy on Equifax, Maintains $350 Price Target

Needham analyst Mike Matson downgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Buy to Hold and maintains the price target from $86 to $86.

Downgrades

Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86

<a href="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/" title="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/">https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/</a>

Tech

AAPL

Reported Earlier, Apple's New iPhone Sales In China Rose 20% In First 3 Weeks

Castor Maritime (CTRM) has released an update. Castor Maritime Inc. has reported a substantial increase in net income to $22.9 million for Q2 2024,...

Castor Maritime Reports Soaring Profits in 2024

Castor Maritime (CTRM) has released an update. Castor Maritime Inc. reports a strong financial position in their latest unaudited condensed consoli...

Castor Maritime Flaunts Solid Financial Growth

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Castor Maritime (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctrm-stock-quote/">CTRM</a>) just reported results for the second quarter of 2024.<ul><li>Castor Maritime reported earnings per share of $1.02.</li><li>The company reported revenue of $16.28 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ctrm-stock-earnings-castor-maritime-for-q2-of-2024/">CTRM Stock Earnings: Castor Maritime Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTRM Stock Earnings: Castor Maritime Reported Results for Q2 2024

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

High-risk, high-reward stocks are highly favored by investors having high risk tolerance to achieve potential returns and yield. Hence, it could be ideal to buy fundamentally solid, high-risk, high-reward penny stocks Taboola.com (TBLA), Ironwood Pharmaceuticals (IRWD), and Castor Maritime (CTRM). Keep reading... Penny stocks are low-priced stocks with small market capitalization. Due to their illiquidity and wide bid-ask spread, they fall in the category of risky and speculative stocks. However, their potential for higher returns at low costs makes them an appealing investment choice.
Amid this backdrop, investors could consider investing in high-risk, high-reward penny stocks Taboola.com Ltd. (<a href="https://stocknews.com/stock/TBLA/">TBLA</a>), Ironwood Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/IRWD/">IRWD</a>), and Castor Maritime Inc. (<a href="https://stocknews.com/stock/CTRM/">CTRM</a>) with significant potential.
The U.S. economy is getting better, as evidenced by the second quarter reports. The <a href="https://www.reuters.com/markets/us/us-economic-growth-regains-steam-second-quarter-inflation-slows-2024-07-25/">economy grew at a 2.8% rate in the second quarter</a>, with solid consumer spending growth and rising business investment. Inflation pressures have also eased recently, raising expectations of an interest rate cut from the Federal Reserve soon.
Amid this, investors attempt to spread their money across different segments and different market caps. Among these are <a href="https://www.investopedia.com/updates/how-to-invest-in-penny-stocks/">penny stocks</a>, which are stocks of small publicly traded companies listed on stock exchanges for a price under $5. Usually, investors with high-risk tolerances turn to these stocks, as these allow investors to hold thousands of shares in a smaller capital.
Penny stocks have a strong advantage over high-priced stocks of possible price spikes to multi-dollar levels where investors stand to be rewarded handsomely by investing significantly less. However, penny stocks are also considered highly volatile and speculative due to their large bid-ask spreads, small market capitalization, and lack of liquidity.
Thus, investors with a high-risk appetite can invest in high-risk, high-reward penny stocks that have higher return prospects and yield handsome rewards.
Given the industry's bright prospects, let's delve into the fundamentals of some of the high-risk, high-reward stocks such as TBLA, IRWD, and CTRM.
Taboola.com Ltd. (<a href="https://stocknews.com/stock/TBLA/">TBLA</a>)
TBLA operates an artificial intelligence-based algorithmic engine platform internationally. The company offers Taboola, a platform that partners with websites, devices, and mobile apps to recommend editorial content and advertisements on the open web to users.
On August 30, TBLA unveiled its performance advertising-focused bidding technology, Maximize Conversions, for all advertisers. Maximize Conversions is an AI-powered technology that allows Taboola advertisers to drive more conversions and lower costs for campaigns.
On August 5, TBLA expanded its partnership with DoubleVerify, the leading software platform for digital media measurement, data, and analytics, with the integration of Doubleverify's authentic marketplace solution, offering brands a more granular way to customize brand safety.
The integration gives brands confidence that their ad investments are matched with the appropriate content environment, leading to better performance.
Also, on July 24, TBLA introduced Taboola for Audience, a new AI-powered technology to empower publishers to drive higher traffic. It combines AI-powered personalization capabilities into a single, unified audience development platform and includes exclusive acquisition channels, reader experience personalization, and actionable audience insights.
TBLA's revenues for the second quarter that ended June 30, 2024, increased 29% year-over-year to $428.20 million. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp">gross profit</a> grew 18.2% from the year-ago value to $144.80 million. The company's adjusted EBITDA came in at $37.23 million, reflecting growth of 137.7% from the prior year's quarter.
In addition, the company's cash and cash equivalents were $182.20 million as of June 30, 2024, compared to $176.11 million as of December 31, 2023.
Street expects TBLA's revenue and EPS for the third quarter (ending September 2024) to increase 19.2% and 321.1% year-over-year to $429.40 million and $0.08, respectively. Also, the company has topped the consensus EPS estimate in all of the trailing four quarters.
Shares of TBLA have surged 0.9% over the past month and 1.5% over the past nine months to close the last trading session at $3.50.
TBLA's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Sentiment, Value, and Growth. Within the A-rated <a href="https://stocknews.com/category/advertising/">Advertising</a> industry, TBLA is ranked #3 out of 16 stocks.
<a href="https://stocknews.com/stock/TBLA/">Click here</a> to access additional ratings of TBLA for Momentum, Stability, and Quality.
Ironwood Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/IRWD/">IRWD</a>)
IRWD is a healthcare company that focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for treating adults suffering from irritable bowel syndrome. It is also developing IW-3300, a GC-C agonist for treating visceral pain conditions.
IRWD's trailing-12-month EBIT margin and levered FCF margin of 29.79% and 24.31% are 1144.3% and 1850% higher than the respective industry averages of 2.39% and 1.25%. Likewise, the stock's trailing-12-month gross profit margin of 67.95% is considerably higher than the industry average of 57.59%.
During the second quarter that ended June 30, 2024, IRWD posted total revenues of $94.40 million. Its income from operations was $24.98 million, against a loss from operations of $1.08 billion in the prior year's quarter. Its non-GAAP net income and adjusted EBITDA amounted to $1.51 million and $27.91 million for the quarter, respectively.
Analysts expect the company's revenue for the fiscal year (ending December 2025) to increase 2.3% year-over-year to $364.50 million, while its EPS for the same period is expected to grow 184.3% year-over-year to $0.33. Moreover, IRWD's shares have declined 28% over the past month to close the last trading session at $5.06.
IRWD's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Value and Quality and a B for Growth. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, IRWD is ranked #33 out of 158 stocks.
In addition to the POWR Ratings we've stated above, we also have IRWD ratings for Stability, Momentum, and Sentiment. Get all IRWD ratings <a href="https://stocknews.com/stock/IRWD/">here</a>.
Castor Maritime Inc. (<a href="https://stocknews.com/stock/CTRM/">CTRM</a>)
Headquartered in Limassol, Cyprus, CTRM provides shipping services globally. The company operates in Dry Bulk Vessels and Containerships segments. It offers seaborne transportation services for dry bulk cargo; and commodities, such as iron ore, coal, soybeans, etc.
On July 16, CTRM entered, through a separate wholly-owned subsidiary, into an agreement to acquire a 2015-built Ultramax dry bulk carrier vessel from an unaffiliated third party for a purchase value of $25.5 million.
With the acquisition, CTRM is entering the Ultramax segment and will work towards its objective of renewing and developing its fleet. The company look forward to seek further opportunities in the shipping space.
On May 28, CTRM completed the previously announced sale of the M/V Magic Horizon, a 2010-built Panamax bulk carrier vessel, for a price of $15.8 million. It expects to generate a net gain of about $4.6 million from the sale.
For the second quarter that ended June 30, 2024, CTRM reported total vessel revenues of $16.28 million. Its operating income rose 104% from the year-ago value to $15.57 million. The company's net income and EPS amounted to $22.85 million and $1.02, up 179.1% and 18.6% from the prior year's quarter, respectively.
Furthermore, the company's adjusted EBITDA grew 86.6% year-over-year to $25.23 million.
CTRM's stock has increased 1.8% over the past six months and 5.6% over the past year to close the last trading session at $4.54.
CTRM's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CTRM has an A grade for Value and Quality. It also has a B grade for Momentum. It is ranked #7 out of 39 stocks in the A-rated <a href="https://stocknews.com/category/shipping/">Shipping</a> industry.
In addition to the POWR Ratings we've stated above, we also have CTRM ratings for Sentiment, Growth, and Stability. Get all CTRM ratings <a href="https://stocknews.com/stock/CTRM/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
TBLA shares were trading at $3.27 per share on Tuesday afternoon, down $0.23 (-6.57%). Year-to-date, TBLA has declined -24.48%, versus a 16.88% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/tbla-irwd-ctrm-3-high-risk-high-reward-penny-stocks-to-buy/>3 High-Risk, High-Reward Penny Stocks to Buy</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Risk, High-Reward Penny Stocks to Buy

Castor Maritime (CTRM) has released an update. Castor Maritime Inc., a global shipping company, successfully conducted its 2024 Annual General Meet...

Castor Maritime's Successful 2024 Shareholders Meeting

Castor Maritime to buy containership vessel for $16.49M

Castor Maritime (CTRM) has released an update. Castor Maritime Inc., a global shipping company, has announced the acquisition of a 2009-built 1,850...

Castor Maritime Expands Fleet with New Acquisition

Castor Maritime (CTRM) has released an update. Castor Maritime Inc., a diversified global shipping company, has announced the purchase of a 2020-bu...

Castor Maritime announces delivery of the M/V Magic Ariel

AMAT

ASTS

ASXC

ATOS

BABA

BATL

BEEM

BEKE

BLDP

BLUE

CARA

CATX

COCP

CSCO

CTRM

ESPR

GLNG

GOEV

GOLD

GRAB

HUYA

IRWD

JAGX

KNDI

LITE

MDAI

MIRA

MMAT

MNDY

NNDM

OGEN

OUST

PSFE

RRAC

SACH

STNE

TAYD

TBLA

TCEHY

TCRT

VUZI

WKHS

XXII

Press Releases

Castor Maritime Inc. Announces Final Results of Tender Offer to Purchase its Outstanding Common Share Purchase Warrants Issued on April 7, 2021

Castor Maritime Inc. Announces the Acquisition of its First Ultramax Vessel

Castor Maritime Inc. Announces the Date of its 2024 Annual General Meeting of Shareholders

Castor Maritime Inc. Reports Net Income of $22.9 Million for the Three Months Ended June 30, 2024 and Net income of $45.2 Million for the Six Months Ended June 30, 2024

Castor Maritime Inc. Announces Delivery of the M/V Magic Celeste

Castor Maritime Inc. Announces Results of its 2024 Annual General Meeting of Shareholders

Castor Maritime Inc. Announces Vessel Acquisition

Contracts

Castor Maritime Inc. Announces Delivery of the M/V Raphaela

Castor Maritime Inc. Announces Delivery of the M/V Magic Ariel

Comments

Castor Maritime

Vendite allo scoperto

Castor Maritime (NASDAQ:CTRM) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO